What Are The Protocol Guidelines For Determining Minimal Erythema Dose (Med) And Setting Initial Parameters For Excimer Laser Treatment Of Vitiligo?

For vitiligo, MED testing and excimer dosing should be based primarily on the depigmented lesion—not simply on the patient’s normal skin phototype. Test spots with incremental fluences are used to identify the lowest dose that produces confluent erythema within approximately 24 hours. Treatment can then begin at the MED or about 50 mJ/cm² below it, with cautious increases of roughly 50 mJ/cm² per session while normal surrounding skin is shielded.

The practical principle is controlled, mild erythema—not maximal redness or sunburn. Completely depigmented lesions may require surprisingly low starting fluences, often around 100–150 mJ/cm², whereas thicker or less responsive anatomical sites may require higher device settings.

Establishing a Reliable MED

What MED means in this setting

The minimal erythema dose (MED) is the lowest fluence that produces a clearly visible, confluent erythematous response at the assessed time point, commonly around 24 hours after exposure.

The endpoint should not be confused with blistering, marked pain, edema, or intense erythema. Those findings indicate excessive exposure rather than an appropriate therapeutic threshold.

Use incremental test spots

Apply several small test spots to the target lesion using progressively higher fluences. The increments should be selected according to the device’s validated protocol and the lesion’s degree of depigmentation.

The lowest test fluence that produces the defined erythema endpoint becomes the lesion-specific MED. Document the fluence, test location, treatment date, and response at follow-up.

Assess the response at the correct interval

Immediate redness is not a dependable MED endpoint. Examine the test area after the protocol-defined interval, typically approximately 24 hours, because the clinically relevant erythematous response may evolve after exposure.

If the response is unclear, avoid assuming that the dose was tolerated. Reassessment or repeat testing at a safer dose is preferable to an aggressive escalation.

Select the Initial Excimer Fluence

Start at or below the measured threshold

Once the MED is established, treatment is commonly initiated at the MED or approximately 50 mJ/cm² below the MED.

Some broader phototherapy protocols begin at a percentage of the measured MED, such as 50–70%, but this approach should not be transferred automatically to excimer treatment of vitiligo. The appropriate starting point depends on the device, lesion, anatomical site, and treating clinician’s protocol.

Completely depigmented lesions need particular caution

A completely depigmented patch has little or no melanin-mediated photoprotection. For this reason, initial fluences are often relatively low—commonly around 100–150 mJ/cm²—even when the patient’s surrounding skin is darker.

Using the surrounding skin phototype as the sole dosing reference can therefore produce excessive erythema or burns in the lesion.

Consider anatomical responsiveness

When a validated MED is unavailable or when a device-specific starting-dose chart is being used, anatomical starting ranges may provide a framework:

Treatment site	Example initial fluence
Periocular skin	100 mJ/cm²
Face, scalp, ears, neck, axilla, bikini area	150 mJ/cm²
Arms, legs, and trunk	200 mJ/cm²
Wrists	250 mJ/cm²
Elbows	300 mJ/cm²
Knees	350 mJ/cm²
Hands and feet	400 mJ/cm²
Fingers and toes	Up to 600 mJ/cm²

These values are starting references, not universal prescriptions. A fully depigmented lesion, thin skin, periocular location, recent sun exposure, or a history of photosensitivity may justify a lower dose.

Titrate According to the Erythema Response

The desired endpoint is mild erythema

The usual therapeutic target is mild, transient erythema that does not progress to significant pain, blistering, ulceration, or prolonged inflammation.

Sunburn-level reactions are not evidence of better treatment. Excessive inflammation can delay subsequent sessions and may increase the risk of complications.

Increase conservatively when there is no response

If no clinical erythema or treatment effect is observed, increase the fluence cautiously, often by approximately 50 mJ/cm² per session.

For patients with particularly sensitive lesions or high-risk anatomical sites, increases may need to occur less frequently or in smaller device-specific increments.

Reduce the dose when erythema is excessive

A practical adjustment framework is:

No visible response: increase by approximately 50 mJ/cm², if clinically appropriate.
Mild erythema: maintain the dose or continue the planned cautious escalation.
Moderate erythema: reduce the next fluence by approximately 50 mJ/cm².
Severe erythema, marked pain, blistering, or tissue injury: withhold treatment until recovery and substantially reduce the subsequent dose; a reduction of approximately 100 mJ/cm² is described in some protocols.

The clinician should also reassess whether the reaction reflects an incorrect dose, recent ultraviolet exposure, photosensitizing medication, or another patient-specific factor.

Protect Normal Surrounding Skin

Shield uninvolved skin

Use UV-protective templates, masks, or equivalent shielding to confine exposure to the vitiligo patch.

This reduces unwanted erythema and tanning of normally pigmented skin and helps ensure that the intended fluence is delivered only to the treatment target.

Match the beam to the lesion

For small or irregular lesions, use an appropriate spot-shaping accessory or adjustable aperture when available. A beam profile that is larger than the lesion can expose healthy skin unnecessarily.

Particular care is required around the eyes, where shielding and device-specific safety procedures are essential.

Understand Why Normal-Skin MED Can Mislead

Normal skin and vitiligo skin are not equivalent test surfaces

Traditional MED phototesting may be performed on a non-sun-exposed site such as the lower back or buttocks. This can characterize general photosensitivity, but it does not necessarily predict the tolerance of an amelanotic vitiligo patch.

The lesion may respond differently from normal skin because of its loss of pigment and because anatomical sites vary in thickness and responsiveness.

Use normal-skin testing selectively

Normal-skin phototesting can be relevant when evaluating unusual photosensitivity, uncertain patient tolerance, or a device-specific safety protocol. However, it should not replace cautious lesion-based dosing when treating depigmented vitiligo.

The key distinction is between a patient-sensitivity test on normal skin and a treatment-threshold test on the target lesion. They are related but not interchangeable.

Understanding the Trade-offs

A lower starting dose may require more sessions

Starting conservatively reduces the risk of severe erythema and treatment interruption. The trade-off is that the clinician may need more sessions or gradual dose escalation before reaching an effective therapeutic range.

Anatomical charts cannot replace clinical observation

Hands, feet, elbows, knees, fingers, and toes may require higher fluences because they can be less responsive. However, a charted dose may still be excessive for a particular patient or lesion.

Clinical response, lesion pigmentation, recent ultraviolet exposure, and adverse effects should take priority over rigid adherence to a nominal table.

More inflammation is not better

Excessive erythema, pain, blistering, or crusting indicates tissue injury rather than superior repigmentation. Treatment should be paused or reduced until the skin has recovered.

Protocols vary by device

Excimer systems differ in calibration, beam profile, spot size, and manufacturer-recommended dosing increments. The treating clinician must reconcile published ranges with the specific device’s validated operating instructions and local clinical protocol.

How to Apply This to a Treatment Protocol

Use the following sequence as a practical framework, subject to clinician assessment and device-specific instructions:

If your primary focus is safety: perform incremental test spots on the target lesion when feasible, identify the lowest dose producing confluent erythema at approximately 24 hours, and start at the MED or about 50 mJ/cm² below it.
If your primary focus is treating a completely depigmented patch: begin conservatively, often around 100–150 mJ/cm², rather than basing the dose only on the surrounding skin phototype.
If your primary focus is an anatomically resistant site: use the relevant anatomical starting range as a guide, but escalate only when the clinical response supports it.
If your primary focus is preventing collateral exposure: shield normal skin and shape the beam to the lesion’s actual size and outline.
If your primary focus is dose escalation: increase by approximately 50 mJ/cm² only when the previous response is inadequate and there is no significant erythema or tissue injury.

A sound vitiligo excimer protocol combines lesion-specific testing, conservative starting fluence, controlled mild erythema, gradual titration, and strict protection of uninvolved skin.

Summary Table:

Treatment site	Example initial fluence
Periocular skin	100 mJ/cm²
Face, scalp, ears, neck, axilla, bikini area	150 mJ/cm²
Arms, legs, and trunk	200 mJ/cm²
Wrists	250 mJ/cm²
Elbows	300 mJ/cm²
Knees	350 mJ/cm²
Hands and feet	400 mJ/cm²
Fingers and toes	Up to 600 mJ/cm²

Ready to elevate your vitiligo treatment outcomes? BELIS offers advanced excimer laser systems designed for precision and safety. Our devices are trusted by clinics worldwide for their reliability and efficacy. Contact us today to learn how our technology can enhance your practice and deliver superior results for your patients. Get in touch with our experts!